Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MALT: cfDNA Monitoring in Metastatic Melanoma
NCT03493230Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Apr 2018
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Open-label trial in Malignant Melanoma (MM), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoints: Plasmatic BRAF and NRAS mutation concentration at 0 days and Longitudinal monitoring of cell-free BRAF and NRAS mutation kinetics at 24 months. Started Apr 2018; status: completed.
02
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT03493230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493230.